ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Chongqing Precision Biotech and Imunopharm Technology side by side

Their registered studies and the programs behind them, as ClinicalTrials.gov shows them and the companies' own pipelines name them. Counts, not rankings: the companies differ in size, so each number is shown beside its share of that company's own programs.

At a glance

Studies each sponsor leads, with the companies grouped under it. Every number opens the studies it counts.

Chongqing Precision BiotechImunopharm Technology
studies on the registry5127
open to participants now3710
phase 3 studies under way00
reach primary completion within a year112
programswith a study of their own in two years113

Pipeline by phase

Each program once, at the furthest phase its own studies reached. The bar is the share of that company's programs, so a small company and a large one read on the same scale.

Furthest phaseChongqing Precision BiotechImunopharm Technology
Phase 1

Chongqing Precision Biotech: 9 of its 11 programs at phase 1

  1. Anti-CD70 CAR-expressing T Lymphocytesphase 1
  2. Targeted CEA CAR-Tphase 1
  3. MC-1-50phase 1
  4. Invivo CAR-Tphase 1
  5. Anti-CD5 CAR NK cellsphase 1

and 4 more — sign in to see them all

82%

Imunopharm Technology: 3 of its 3 programs at phase 1

  1. IM96phase 1
  2. ZM001phase 1
  3. Engineering of chimeric antigen receptors targeting CD19 in allogeneic T cellsearly phase 1
100%
Phase 2

Chongqing Precision Biotech: 2 of its 11 programs at phase 2

  1. CEA-targeted CAR-T cellsphase 2
  2. CD19 CAR-T cellsphase 2
18%
00%
Phase 300%00%
Approved, new studies00%00%

Readouts ahead

Programs whose next study reaches primary completion in each month, by the sponsor's own estimate. A ring marks a month with a phase 3 readout.

Nov ’26DecJan ’27FebMarAprMayJunJulAugSepOct
Chongqing Precision Biotech5 readouts · 0 phase 3·

Chongqing Precision Biotech, Dec ’26: 4 programs whose next study reaches primary completion

  1. PIC1 Injectionphase 1 · Dec 0 · NCT07456371
  2. Anti-CD70 CAR-expressing T Lymphocytesphase 1 · Dec 31 · NCT06215950
  3. CEA-targeted CAR-T cellsphase 2 · Dec 31 · NCT06043466
  4. Targeted CEA CAR-Tphase 1 · Dec 31 · NCT06768151
··

Chongqing Precision Biotech, Mar ’27: 1 program whose next study reaches primary completion

  1. Anti-CD5 CAR NK cellsphase 1 · Mar 31 · NCT06909474
·······
Imunopharm Technology1 readouts · 0 phase 3······

Imunopharm Technology, May ’27: 1 program whose next study reaches primary completion

  1. IM96phase 1 · May 5 · NCT07406984
·····
size: programs that monthincludes phase 3Dates are estimates the sponsors file and often move.

Changed in the last 90 days

Since Aug 22, 2026: programs whose first study was registered, programs that reached a new phase, studies stopped, and primary completions moved later (a month or more in phase 3, three otherwise). Stops and dates are read from the registry’s changes, kept since Sep 25, 2026.

Chongqing Precision Biotech

New programs 0

None

Reached a new phase 0

None

Study stopped 0

None

Primary completion later 0

None

Imunopharm Technology

New programs 0

None

Reached a new phase 0

None

Study stopped 0

None

Primary completion later 0

None

Where they overlap

Conditions where at least two of them have programs: 2 in all. A program counts in each condition its studies name most.

ConditionChongqing Precision BiotechImunopharm Technology
Lupus Erythematosus, Systemicboth · compare here

Chongqing Precision Biotech in Lupus Erythematosus, Systemic: 4 programs

  1. CD19 CAR-T cellsphase 2
  2. Anti-CD70 CAR-expressing T Lymphocytesphase 1
  3. MC-1-50phase 1
  4. PTOC1phase 1

Their studies: Chongqing Precision Biotech’s studies of Lupus Erythematosus, Systemic in search

Colorectal Neoplasmsboth · compare here

Chongqing Precision Biotech in Colorectal Neoplasms: 1 program

  1. CEA-targeted CAR-T cellsphase 2

Their studies: Chongqing Precision Biotech’s studies of Colorectal Neoplasms in search

Imunopharm Technology in Colorectal Neoplasms: 1 program

  1. IM96phase 1

Their studies: Imunopharm Technology’s studies of Colorectal Neoplasms in search

Same targetBetaPro · free during the beta

Programs that act on the same gene, from the company’s own words, a judged reading of NCIt, ChEMBL or the studies, or a rule. A reading by rule is marked rule.

No gene two of them both target, among the programs whose target is known.

A target, or a pathogen for a vaccine, known for: Chongqing Precision Biotech 1 of 11 · Imunopharm Technology 0 of 3 programs (1 of them by rule). Most early programs are named only by a code and their companies do not say what they act on, so this list is short and grows as targets are read.

What this can't show

  • Only what ClinicalTrials.gov holds: programs run only in other registries are missing.
  • Grouping is ours: subsidiaries and acquisitions counted under the parent, each dated and sourced on the sponsor page.
  • Readout dates are the sponsors’ estimates, not results.
  • A program is a drug as the registry names it: a code its company has not tied to a name counts on its own until it is read, and a study run under a partner’s name counts for the partner.
  • “Same target” covers only the programs whose target is known, from the company’s words, a judged reading or a rule; most early programs say nothing of it.